Jeremy G. Chadwick Declares Sale of Shares in Kymera Therapeutics, Inc.

On March 3rd, Jeremy G. Chadwick, the Chief Operating Officer of Kymera Therapeutics, Inc. (NASDAQ:KYMR), divested 1,383 shares of the company's stock. The shares were sold at an average price of $30.45, amounting to a total value of $42,112.35. Following this transaction, Chadwick maintains ownership of 67,800 shares, which are valued at approximately $2,064,510. This sale reflects a 2.00% decrease in his overall holding in the business. The transaction was made public through a filing with the Securities and Exchange Commission (SEC), which can be accessed online.

Kymera Therapeutics Stock Performance

On the same day as the sale, Kymera Therapeutics stock experienced a decline of 3.8%, closing at $30.17. A total of 982,064 shares changed hands, in comparison to the average trading volume of 578,939 shares. The company has a fifty-day moving average price of $38.81 and a two-hundred-day moving average price of $43.66. Over the past year, Kymera's stock has reached a low of $29.16 and a high of $53.27. The market capitalization of Kymera Therapeutics stands at about $1.95 billion, with a price-to-earnings (PE) ratio of -12.89 and a beta of 2.18.

Recent Earnings Report

Kymera Therapeutics released its most recent quarterly earnings data on February 27th. The company reported earnings per share (EPS) of ($0.88) for the quarter, which was below analysts' consensus estimate of ($0.76) by $0.12. Revenue for the quarter came in at $7.39 million, significantly lower than the expected $14.81 million. The firm is facing challenges, as indicated by a negative net margin of 191.26% and a negative return on equity of 24.96%. Analysts are forecasting an EPS of -2.79 for the current fiscal year.

Analyst Opinions

Brokerage firms have provided various insights regarding Kymera Therapeutics. UBS Group recently lowered its target price from $80.00 to $74.00 while maintaining a "buy" rating. Morgan Stanley increased its price target from $45.00 to $49.00 and rated the stock as "equal weight". In addition, BMO Capital Markets started coverage on Kymera with a "market perform" rating and a target price of $55.00. Leerink Partners reaffirmed an "outperform" rating with a price target of $60.00, and Stephens echoed this sentiment. Currently, three analysts rate the stock as a hold, while ten analysts have a buy rating, and one has assigned it a strong buy rating. MarketBeat reports that the stock holds a consensus rating of "Moderate Buy" with an average price target of $56.69.

Institutional Investments

Recently, significant adjustments to holdings in Kymera Therapeutics were reported by several institutional investors. Massachusetts Financial Services Co. MA increased its stake by 11.7%, now holding 453,377 shares worth approximately $21.45 million. Eventide Asset Management LLC raised its position by 9.9%, owning 507,902 shares valued at about $24.04 million. Furthermore, JPMorgan Chase & Co. significantly boosted its position by 212.6%, acquiring an additional 95,547 shares, resulting in a total of 140,491 shares valued at $6.65 million. Natixis Advisors LLC and Intech Investment Management LLC also made recent investments in Kymera Therapeutics.

Company Overview

Kymera Therapeutics, Inc. is focused on developing innovative small molecule therapies that selectively degrade disease-causing proteins. Their main programs include an IRAK4 program, which is currently in Phase II clinical trials for treating immunology-inflammation diseases, and a STAT3 program targeting hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis.

Stocks, Trading, Investing